| brain tumor |
phenotype |
6 |
— |
brain tumors |
| BRAP |
phenotype |
2 |
1 |
|
| BRCA1 |
gene |
22 |
3 |
|
| BRCA2 |
gene |
16 |
3 |
BRCA216 |
| BrdU |
drug |
6 |
4 |
5 μM BrdU, 5-bromo-2'-deoxyuridine, BrdU slow-release pellet, BrdU+, BrdU-IR, bromodeoxyuridine |
| breast cancer |
phenotype |
40 |
15 |
BC, BRCA1-associated breast cancer, BRCA2-associated breast cancer, breast, breast cancer, breast cancer cells, breast cancer risk, breast cancer susceptibility, breast cancers, breast carcinoma, invasive breast cancer |
| breast cancer risk |
phenotype |
2 |
2 |
breast cancer |
| BRG1 |
gene |
4 |
2 |
Brg1, SMARCA4 |
| Bruker mass spectrometry workstation |
drug |
2 |
— |
Bruker |
| BSA |
drug |
25 |
9 |
1% BSA, A2153, Bovine Serum Albumin, Bovine serum albumin, bovine serum albumin, fatty-acid free bovine serum albumin |
| BTBD3 |
gene |
2 |
1 |
BTB/POZ domain-containing 3 |
| bulimia nervosa |
phenotype |
8 |
3 |
BN |
| bullying |
phenotype |
4 |
2 |
bullying |
| buprenorphine |
drug |
10 |
9 |
BUP, buprenorphine prescription status, buprenorphine treatment days, buprinorphine, subcutaneous buprinorphine |
| bupropion |
drug |
11 |
9 |
BUP, Wellbutrin, Zyban, bupropion 150 mg SR-sustained release tablets, bupropion SR, bupropion sustained-release, buproprion |
| C12orf51 |
gene |
3 |
3 |
chromosome 12 ORF 51 |
| C15orf53 |
gene |
3 |
2 |
C15ORF53 region |
| C17orf58 |
gene |
2 |
1 |
|
| C1qa |
gene |
3 |
2 |
C1qa |
| C1qb |
gene |
3 |
1 |
C1qb |
